Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Head & Neck 1CNS 1Breast 1

Conditions

Unipolar Major Depression 1Radiation Injuries 1Head and Neck Neoplasms 1Glioblastoma 1Depression 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Vortioxetine × Clear all
NCT07284628 2025-12-16

ReVoGlio

University of Zurich

Phase 2 Not yet recruiting
78 enrolled
CNS

Glioblastoma

NCT04818099 2021-03-26

Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Unknown
208 enrolled
Head & Neck

Depression, Head and Neck Neoplasms, Radiation Injuries

NCT02637466 2016-09-30

Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers

University of Miami

Phase 4 Withdrawn
Breast

Unipolar Major Depression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡